Q-omics provides the consensus-scored PCDHA5 profile across patient tissues and cancer cell-line models. PCDHA5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PCDHA5 is differentially expressed in 7, with the highest sampling consensus in READ. Additionally, PCDHA5 RNA expression shows 10,979 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, READ, and TGCT as cancer lineages where PCDHA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHA5 survival associations across molecular data types. PCDHA5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHA5 RNA expression–survival associations across cancer types. High PCDHA5 expression shows unfavorable associations in LUSC, THCA, UCEC and KIRP, but favorable associations in UVM and LGG. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for PCDHA5 RNA expression.
This table summarizes PCDHA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHA5 shows lower tumor expression in READ and higher tumor expression in BRCA, LUAD, THCA, ESCA and PRAD. The READ box plot shows higher PCDHA5 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p = .008).
This table shows molecular features associated with PCDHA5 in patient tissues and cancer cell lines. In patient samples, PCDHA5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
